We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+12.67%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.74B
AUM Growth
+$261M
Cap. Flow
+$250M
Cap. Flow %
14.34%
Top 10 Hldgs %
44.01%
Holding
80
New
16
Increased
10
Reduced
40
Closed
8

Top Buys

Rank Stock Value
1
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$111M
2
BBIO icon
BridgeBio Pharma
BBIO
+$75.8M
3
STOK icon
Stoke Therapeutics
STOK
+$50.2M
4
QURE icon
uniQure
QURE
+$38.2M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$25.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$34.5M
2
ZGNX
Zogenix, Inc.
ZGNX
+$24.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$23.9M
4
ARGX icon
argenx
ARGX
+$15.9M
5
ANAB icon
AnaptysBio
ANAB
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
76
Kiniksa Pharmaceuticals
KNSA
$5.73B
– –
-270,000
Closed -$4.88M
SLDB icon
77
Solid Biosciences
SLDB
$790M
– –
-16,667
Closed -$2.3M
MYOV
78
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-650,000
Closed -$15.5M
TBIO
79
DELISTED
Translate Bio, Inc. Common Stock
TBIO
– –
-454,549
Closed -$4.63M
ZGNX
80
DELISTED
Zogenix, Inc.
ZGNX
– –
-450,000
Closed -$24.8M
1 2 3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Cormorant Asset Management's Q2 2019 Portfolio in Review

As of Q2 2019, Cormorant Asset Management held 80 positions worth $1.74B, up 18% from $1.48B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management deployed $250M of net new capital in Q2 2019, opening 16 new positions and adding to 10 existing holdings. Its largest new stake was Turning Point Therapeutics, Inc. Common Stock: 3,122,367 shares worth $127M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was InflaRx, an estimated $34.5M trimmed.

  • Cormorant Asset Management's largest Q2 2019 buy was Turning Point Therapeutics, Inc. Common Stock: 3,122,367 shares worth $127M.
  • Cormorant Asset Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019, an estimated $25.4M increase.
  • Cormorant Asset Management's biggest Q2 2019 reduction was InflaRx, cutting an estimated $34.5M.
  • Cormorant Asset Management fully exited Zogenix, Inc. in Q2 2019, selling an estimated $24.8M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $1.74B portfolio in Q2 2019.
  • Cormorant Asset Management opened 16 new positions and closed 8 in Q2 2019.
  • Cormorant Asset Management's portfolio value rose 18% quarter-over-quarter to $1.74B.

Based on Cormorant Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.